Nurix Therapeutics Inc reports results for the quarter ended in May - Earnings Summary

Nurix Therapeutics

13/07/2023 21:50

* Nurix Therapeutics Inc  NRIX.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in May. The
mean expectation of ten analysts for the quarter was for a loss
of 56 cents per share.
    * Revenue rose 168.3% to $30.68 million from a year ago;
analysts
expected $26.22 million. 
    * Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 17% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Nurix Therapeutics Inc shares had fallen by 0.1% this
quarter and lost 9.1% so far this year.
    * The company reported a quarterly loss of $24.28 million.
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $28.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data July
13 at 08:49 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 May. 31 2023      -0.56          -0.45          Beat
 Feb. 28 2023      -0.87          -0.75          Beat
 Nov. 30 2022      -0.79          -0.87          Missed
 Aug. 31 2022      -0.98          -0.90          Beat